Intec Pharma Ltd (NASDAQ:NTEC) gapped down before the market opened on Thursday . The stock had previously closed at $4.40, but opened at $4.62. Intec Pharma shares last traded at $4.95, with a volume of 22,829 shares changing hands.

A number of equities research analysts have issued reports on NTEC shares. Maxim Group reissued a “buy” rating and set a $9.00 target price on shares of Intec Pharma in a research note on Tuesday, April 5th. Zacks Investment Research lowered shares of Intec Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, April 12th.

The company’s market capitalization is $58.61 million. The stock’s 50 day moving average price is $4.54 and its 200 day moving average price is $4.11.

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.